retatrutide clinical trial results weight loss for loss: Study shows 30% body weight Retatrutide Helped Adults With Obesity

The $299 per month injectable floor is accessible but not meaningfully cheaper than what compounded GLP-1 platforms have been offering and compounded platforms can write new prescriptions through telehealth without the scheduled consultation wait time

Multiple lipid species were decreased in both surgical groups at 30 minutes, consistent with postprandial rises in insulin secretion

On April 1, the FDA approved Foundayo (orforglipron), Eli Lillys once-daily oral GLP-1 receptor agonist for obesity, which is the first oral GLP-1 approved for weight management and the fastest new molecular entity approval since 2002

95% CI, 0.64-0.97)